We develop new pharmaceutical products for the treatment of genitourinary tumors and related diseases

News Releases

2020-11-28
Asieris Pharmaceuticals today announced it has been awarded “the Top 100 China Innovative Pharmaceutical Enterprises” at the 2020 Hangzhou China Healthcare Summit of Entrepreneurs, Scientists and Investors…
View Details >

2020-11-12
Asieris Pharmaceuticals announced today that the first patient was enrolled in and administered the global, multi-centered Phase III clinical trial of its photodynamic drug-device combination product, APL-1702 (Cevira®)….
View Details >

2020-11-11
Today Asieris Pharmaceuticals announced the completion of their Series D Round of financing. This round of funding was led by Qiming Venture Partners, and joined by YF Capital, CICC Transfer Fund, V-Capital, Hengxu Capital, Homsun…
View Details >

2020-10-30
“This Phase III clinical trial for the first-line treatment of NMIBC, a key step to verify the advantages and characteristics of APL-1202, is another milestone of Asieris,” commented Dr. Kevin Pan, founder and CEO of Asieris…
View Details >

2020-10-29
APL-1501, which is independently developed by the Prodrug Accurate Drug Delivery (PADD) platform of Asieris, is an oral sustained-release product based on….
View Details >

2020-07-08
Asieris has received Clinical Trial Approval (CTA) from China’s National Medical Products Administration (NMPA) for the global, multi-centered Phase III clinical trial of its photodynamic drug-device…
View Details >

Technology

Bladder cancer and other genitourinary tumors, Tumor immunotherapy…

      More >

APL-1202, APL-1702, APL-1301, APL-1401, APL-1501

Using the world’s leading drug R&D concepts to establish a unique drug R&D system

      More >

Partner With Us

Contact us today for partnership opportunities